[HTML][HTML] Improved early detection of ovarian cancer using longitudinal multimarker models
HJ Whitwell, J Worthington, O Blyuss… - British journal of …, 2020 - nature.com
British journal of cancer, 2020•nature.com
Background Ovarian cancer has a poor survival rate due to late diagnosis and improved
methods are needed for its early detection. Our primary objective was to identify and
incorporate additional biomarkers into longitudinal models to improve on the performance of
CA125 as a first-line screening test for ovarian cancer. Methods This case–control study
nested within UKCTOCS used 490 serial serum samples from 49 women later diagnosed
with ovarian cancer and 31 control women who were cancer-free. Proteomics-based …
methods are needed for its early detection. Our primary objective was to identify and
incorporate additional biomarkers into longitudinal models to improve on the performance of
CA125 as a first-line screening test for ovarian cancer. Methods This case–control study
nested within UKCTOCS used 490 serial serum samples from 49 women later diagnosed
with ovarian cancer and 31 control women who were cancer-free. Proteomics-based …
Background
Ovarian cancer has a poor survival rate due to late diagnosis and improved methods are needed for its early detection. Our primary objective was to identify and incorporate additional biomarkers into longitudinal models to improve on the performance of CA125 as a first-line screening test for ovarian cancer.
Methods
This case–control study nested within UKCTOCS used 490 serial serum samples from 49 women later diagnosed with ovarian cancer and 31 control women who were cancer-free. Proteomics-based biomarker discovery was carried out using pooled samples and selected candidates, including those from the literature, assayed in all serial samples. Multimarker longitudinal models were derived and tested against CA125 for early detection of ovarian cancer.
Results
The best performing models, incorporating CA125, HE4, CHI3L1, PEBP4 and/or AGR2, provided 85.7% sensitivity at 95.4% specificity up to 1 year before diagnosis, significantly improving on CA125 alone. For Type II cases (mostly high-grade serous), models achieved 95.5% sensitivity at 95.4% specificity. Predictive values were elevated earlier than CA125, showing the potential of models to improve lead time.
Conclusions
We have identified candidate biomarkers and tested longitudinal multimarker models that significantly improve on CA125 for early detection of ovarian cancer. These models now warrant independent validation.
nature.com
